Reach Us +44-1647-403003
Molecular Targeted Immunotherapy Of Cancer: The Future Of Drug Innovation | 22620
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Molecular targeted immunotherapy of cancer: The future of drug innovation

4th World Congress on Cancer Science & Therapy

Debora Dummer Meira

ScientificTracks Abstracts: J Cancer Sci Ther

DOI: 10.4172/1948-5956.S1.033

This lecture will focus on a variety of topics related to tumour immunology & immunotherapy for clinical evaluation of candidate therapeutics for treating several types of tumors, and will include discussion of: Hallmarks of Cancer: Applications to cancer medicine; Targeted therapies in medical oncology: successes, failures and next steps; Inflammation in the genesis and perpetuation of cancer; Linking stress system activity and immunity dysregulation to cancer development and progression: inflammation in the genesis and perpetuation of cancer; Prognostic value and rationale of immunotherapy development; Antibody therapy of cancer/Immunotherapy: combination and dosing schedule are key; Identification of therapeutic targets for Immunomodulation and Cancer chemoprevention. In addition to these subjects, attendees of this lecture will be familiarized with the need for rigorous and stringent testing of candidate immunotherapeutics, so that only the most promising therapies are advanced to clinical trial evaluation of efficacy when treating patients in the era of Translational Oncology, from the bench to the bedside.
Debora Dummer Meira is Pharmacyst specialized in Biochemistry, Master?s Pharmaceutical Sciences and PhD in Biosciences/Molecular Oncology at Brazilian National Cancer Institute. She has studied tumor molecular biology and therapeutics for more than 15 years and has authored several peer-reviewed reports. She is a member of the Scientific Brazilian Pharmaceutical Society in Oncology and President of Espirito Santo section. She also has experience in Pharmaceutical Sciences, Targeted therapies in Oncology, Cancer Immunology & immunotherapy and Cancer Chemoprevention. Currently, is she is Professor and Researcher at Federal University of Esp?rito Santo looking for agents to reverse, suppress and prevent carcinogenic progression and New Drugs in Cancer Immunotherapy.
Relevant Topics